ClinicalTrials.gg
AvailableNCT05572996Updated Oct 10, 2022

Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease

An expanded access record providing Inhaled Treprostinil in Pulmonary Hypertension, Interstitial Lung Disease and Combined Pulmonary Fibrosis and Emphysema, sponsored by Ferrer Internacional S.A.. Available. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-10.

Sponsored by Ferrer Internacional S.A. · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
Ages
18 Years and older
Sex
All
01

Study summary

This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.

02

Conditions studied

  • Pulmonary Hypertension
  • Interstitial Lung Disease
  • Combined Pulmonary Fibrosis and Emphysema

Keywords

  • Inhaled Treprostinil
  • Tyvaso
  • EAP
  • Expanded Access
  • Early Access
  • Compassionate Use
  • Named Patient Program
  • NPP
  • PH-ILD
03

In context

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Lead sponsor

Ferrer Internacional S.A. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient consent
  2. Males and females aged 18 years old or older
  3. PH-ILD diagnosis:

    • Confirmed diagnosis of Group 3 PH by Right Heart Catheterization (RHC):

      • mPAP > 20 mmHg with PAWP ≤ 15 mmHg and PVR ≥ 2 WU and
    • Confirmed diagnosis of diffuse parenchymal lung disease based on imaging (any form of ILD or CPFE)

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of PAH or PH for reasons other than Group 3 PH-ILD
  2. Use of concomitant PAH drugs for PH-ILD (ambrisentan and riociguat)
  3. Use of any concomitant drug
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT05572996
Responsible party
Sponsor
First posted
Oct 10, 2022
Last update
Oct 10, 2022

Study contacts

Ferrer Medical Information
Contact
medinfo@ferrer.com
+34 629 966 806
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion